Semaglutide

Plain-language summary

A GLP-1 receptor agonist FDA-approved for type 2 diabetes (Ozempic/Rybelsus) and chronic weight management and cardiovascular risk reduction (Wegovy).

Regulatory status

Evidence snapshot

Established. Supported by multiple well-conducted randomized trials and/or systematic reviews with consistent results.

How it works

Mimics the gut hormone GLP-1, enhancing glucose-dependent insulin release, suppressing glucagon, slowing gastric emptying, and reducing appetite through effects on brain satiety centers.

Approved uses and researched uses

Researched uses are studied but not FDA-approved and may be off-label. This is not a recommendation to use them.

Known risks and uncertainties

Common effects are nausea, vomiting, diarrhea, and constipation. Less common but serious risks include pancreatitis, gallbladder disease, and possible worsening of diabetic retinopathy. The label carries a boxed warning for thyroid C-cell tumors based on rodent studies.

Cautions and contraindications

Contraindicated in people with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2), and in those with prior serious hypersensitivity to semaglutide.

Consumer considerations

• FDA-approved brand versions differ from compounded "semaglutide" sold by some telehealth outlets.
• Weight often returns after stopping unless lifestyle changes are maintained.
• Dose is escalated gradually to limit GI side effects.
• Ozempic and Wegovy are the same molecule but approved for different uses and doses.
• Cost and insurance coverage vary widely by indication.

Questions to ask a licensed clinician

• Is this being prescribed for diabetes, weight, or cardiovascular risk, and which brand?
• How should I manage nausea or other GI side effects?
• What happens to my weight or blood sugar if I stop?
• Do my personal or family medical history create any contraindications?
• How will we monitor for pancreatitis or gallbladder problems?

Sources